U.K. and CA companies to collaborate on breast cancer Dx study

The U.K.'s Abcodia will work with California-based OncoCyte to perfect a blood test for early breast cancer detection. Neither side is disclosing financial terms. The collaboration is expected to focus on OncoCyte's PanC-Dx test, which is also in other clinical studies for bladder, breast and lung cancer. For this new study, OncoCyte will test how well PanC-Dx's cancer markers help detect breast cancer in patient samples supplied from Abcodia's biobank. OncoCyte is a subsidiary of BioTime ($BTX). Release

Suggested Articles

Invitae aims to expand its genetic counseling reach through the $50 million acquisition of Clear Genetics, developers of digital chatbot software.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.

HDL unveiled data showing its treatment reduced reduced coronary artery damage in patients with a genetic disorder that causes high cholesterol.